Amgen breaks ground on $200m biomanufacturing facility in US

This article was originally published here

The company expects to invest up to $200m in the approximately 120,000ft² biomanufacturing plant at its West Greenwich campus in Rhode Island. Amgen will use its next-generation biomanufacturing

The post Amgen breaks ground on $200m biomanufacturing facility in US appeared first on Pharma Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply